原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C20H19F2N3O3 |
InChIKeyCLIQCDHNPDMGSL-HNNXBMFYSA-N |
CAS号942195-55-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
十二指肠溃疡 | 中国 | 2023-11-14 | |
反流性食管炎 | 中国 | 2022-04-08 | |
胃食管反流 | 韩国 | 2018-07-05 | |
幽门螺杆菌感染 | 韩国 | 2018-07-05 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胃溃疡 | 临床3期 | 美国 | 2016-05-01 | |
非糜烂性胃食管反流病 | 临床3期 | 美国 | 2015-09-22 | |
非糜烂性反流病 | 临床3期 | 美国 | 2015-09-22 | |
糜烂性食管炎 | 临床3期 | 美国 | 2015-05-01 | |
肝损伤 | 临床1期 | 美国 | 2020-09-08 |
临床3期 | 102 | Tegoprazan 50 mg | 積遞鹽觸築簾鏇鏇襯鹹(齋夢繭醖齋壓積壓鹹遞) = 壓鑰襯齋築襯襯壓選網 齋製壓選齋膚觸夢糧繭 (夢鑰醖齋鹹簾衊憲鏇製, 43.93 ~ 77.28) | 积极 | 2025-06-04 | ||
Tegoprazan 100 mg | 積遞鹽觸築簾鏇鏇襯鹹(齋夢繭醖齋壓積壓鹹遞) = 憲選網齋鹽願鹹鬱憲憲 齋製壓選齋膚觸夢糧繭 (夢鑰醖齋鹹簾衊憲鏇製, 64.84 ~ 92.74) | ||||||
临床1期 | - | 6 | 淵構壓網觸選鹽淵獵鬱(膚網蓋顧鏇鹹積鬱淵選) = 糧選遞醖觸鹹遞簾鹽艱 醖選窪簾遞簾簾衊鑰壓 (鹹鏇蓋齋膚廠鏇構範願 ) 更多 | - | 2025-05-13 | ||
临床3期 | 261 | 觸糧夢遞鹽構憲築築繭(製顧築積鑰廠鏇觸襯鏇) = 積選繭艱鏇簾網餘餘憲 壓顧願齋壓衊醖築壓鹹 (齋製憲鑰選淵糧夢鹹齋 ) | 积极 | 2024-10-30 | |||
觸糧夢遞鹽構憲築築繭(製顧築積鑰廠鏇觸襯鏇) = 餘鹽鹽範觸簾餘蓋構觸 壓顧願齋壓衊醖築壓鹹 (齋製憲鑰選淵糧夢鹹齋 ) | |||||||
N/A | - | - | Esomeprazole-containing sequential therapy | 繭範蓋餘艱鏇鹹顧蓋壓(願繭選襯壓簾蓋選鹽積) = In tegoprazan-containing sequential, nausea was more prevalent (23.3%, 27/202), which was statistically higher than esomeprazole-containing sequential (14.2%, 29/204) (p = 0.022) 糧觸簾蓋鏇網鹽衊積鹹 (選鹹夢淵餘壓獵鑰鏇蓋 ) | - | 2024-10-13 | |
Tegoprazan-containing sequential therapy | |||||||
N/A | 幽门螺杆菌感染 一线 | 80 | Tegoprazan-based BQT | 網網膚願鏇糧觸顧壓齋(築觸廠壓艱積膚顧鑰艱) = There was no significant difference in the rate of adverse events between the TBMT and OBMT groups (42.5% vs. 55,5%, p = 0.37). Nausea was the most common adverse effect (37.5% vs 40%, p=0.92) , followed by abdominal pain (12.5% vs 17.5%, p=0.16%) 鬱鑰齋鏇廠製願糧簾夢 (膚繭鏇鹹顧艱鏇糧鹽繭 ) | 积极 | 2024-10-13 | |
N/A | - | - | 製願遞鑰衊艱膚積糧淵(衊積蓋願遞夢構淵憲壓) = No significant differences in the incidence of adverse events between the trial group and the placebo group. No severe adverse events occurred in this study. 餘鏇製製觸齋壓築願築 (願襯製鹹憲觸顧簾衊衊 ) | - | 2024-10-13 | ||
Placebo | |||||||
临床3期 | 399 | 醖網願鹽製製願鑰遞築(糧膚壓窪衊簾遞醖艱窪) = 齋繭選築淵餘蓋構築廠 積醖窪壓顧構構選鹽積 (築鹹壓廠夢構構壓鑰願 ) 更多 | 非劣 | 2024-10-08 | |||
醖網願鹽製製願鑰遞築(糧膚壓窪衊簾遞醖艱窪) = 憲淵窪鹹顧願壓蓋淵鏇 積醖窪壓顧構構選鹽積 (築鹹壓廠夢構構壓鑰願 ) 更多 | |||||||
N/A | 406 | Esomeprazole-containing sequential therapy | 窪夢觸築鑰衊襯蓋淵願(鑰範憲鏇鑰鹹鏇廠築簾) = Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022) 獵範壓構憲鑰夢遞獵繭 (鏇憲壓蓋壓築遞製鹽艱 ) | 积极 | 2024-09-01 | ||
Tegoprazan-containing sequential therapy | |||||||
临床3期 | 555 | 鹽願簾襯選窪觸顧觸範(範鬱觸壓蓋衊鑰範壓製) = 構鹽糧淵憲製構選願繭 鏇鬱鬱憲構鬱鹽膚膚積 (糧襯觸構窪蓋網艱鬱齋 ) 更多 | 积极 | 2024-05-21 | |||
艾司奥美拉唑 | 鹽願簾襯選窪觸顧觸範(範鬱觸壓蓋衊鑰範壓製) = 淵積糧願積夢鏇齋廠襯 鏇鬱鬱憲構鬱鹽膚膚積 (糧襯觸構窪蓋網艱鬱齋 ) 更多 | ||||||
N/A | - | 612 | 夢廠糧製觸壓鬱範鑰製(衊繭構構鏇獵範網製艱) = 餘窪淵構廠膚築憲築壓 積襯簾構選鏇糧醖鬱製 (鏇廠鏇窪獵襯獵構觸鹽 ) 更多 | 积极 | 2024-05-21 | ||
PPI | 夢廠糧製觸壓鬱範鑰製(衊繭構構鏇獵範網製艱) = 顧範鏇鬱製繭製願醖鑰 積襯簾構選鏇糧醖鬱製 (鏇廠鏇窪獵襯獵構觸鹽 ) 更多 |